Karyopharm Reports Q1 Revenue of $35.1M, Exceeding Expectations
Reports Q1 revenue $35.1M, consensus $31.4M. "As we move through 2026, Karyopharm is in a pivotal period with meaningful clinical and regulatory milestones ahead," said CEO Richard Paulson. "Through Q2 and Q3 of 2026, we expect several important developments that have the potential to create significant value for the company, while improving outcomes for patients. In endometrial cancer, we have completed enrollment in our Phase 3 XPORT-EC-042 trial and remain on track to report topline data in mid-2026. In myelofibrosis, the Phase 3 SENTRY results reinforced the potential of selinexor to meaningfully improve patient outcomes, including a statistically significant SVR35 benefit and a promising overall survival signal. With the endometrial cancer readout ahead and the myelofibrosis regulatory and guideline path coming into focus, we believe these programs could meaningfully expand the impact and long-term opportunity of the selinexor franchise."
